This topic contains a solution. Click here to go to the answer

Author Question: In the international razor blade market, Gillette was considered A) to have no advantage in ... (Read 94 times)

RODY.ELKHALIL

  • Hero Member
  • *****
  • Posts: 591
In the international razor blade market, Gillette was considered
 
  A) to have no advantage in market timing.
  B) a first-mover.
  C) the lowest cost provider.
  D) a late mover.

Question 2

Scale of involvement is
 
  A) lowest when the firm exports its products to the foreign country.
  B) lowest when the firm has a wholly owned subsidiary in the foreign country.
  C) unrelated to the mode of entry.
  D) highest with franchising in the foreign country.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

sarahccccc

  • Sr. Member
  • ****
  • Posts: 318
Answer to Question 1

B

Answer to Question 2

A




RODY.ELKHALIL

  • Member
  • Posts: 591
Reply 2 on: Jul 6, 2018
Wow, this really help


bassamabas

  • Member
  • Posts: 294
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

Complications of influenza include: bacterial pneumonia, ear and sinus infections, dehydration, and worsening of chronic conditions such as asthma, congestive heart failure, or diabetes.

Did you know?

About 60% of newborn infants in the United States are jaundiced; that is, they look yellow. Kernicterus is a form of brain damage caused by excessive jaundice. When babies begin to be affected by excessive jaundice and begin to have brain damage, they become excessively lethargic.

Did you know?

Approximately 15–25% of recognized pregnancies end in miscarriage. However, many miscarriages often occur before a woman even knows she is pregnant.

Did you know?

Asthma is the most common chronic childhood disease in the world. Most children who develop asthma have symptoms before they are 5 years old.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library